Certificate Course in Pharmaceutical Market Access

Twenty-one hours of teaching, six worked case studies, five AI role plays, fifteen quizzes with 197 questions, a 40-question final exam and 88 downloadable resources. Updated through 2026.

Market access decides whether a medicine that works ever reaches a patient. This course teaches the whole discipline - what to prove and against which comparator, what a product is worth, what price to ask for and to accept, which patients to fund first, and where to launch - across both the European and the American systems.

What is inside

• Foundations. What market access actually is, the access value chain, five payer archetypes, and why list price, net price, payer cost and patient cost are four different numbers.

• The United States. Pharmacy benefit managers, rebates, formulary tiers and prior authorisation, Medicare Part B and Part D, Medicaid best price, 340B, and the Inflation Reduction Act as it stands in 2026.

• Health technology assessment and health economics. QALYs, ICERs, budget impact, systematic review and meta-analysis, patient-reported outcomes, indirect comparisons and critical appraisal.

• Europe and the EU HTA Regulation. Joint clinical assessment as it has actually run since January 2025: scope, submission, the HTA IT platform, PICO consolidation and joint scientific consultations.

• Pricing, real-world evidence, early access, negotiation, regulatory affairs, biosimilars and generics, plus where artificial intelligence genuinely changes this work and where it does not.

What you do, not just watch

• Six case studies with real numbers. Choose a phase 3 comparator four weeks before the protocol locks. Decide between two offers from a benefit manager covering 42 million lives. Find three errors in a cost-effectiveness model before the assessment body does. Sequence five launches under international reference pricing. Prioritise seven PICO comparisons when you have data for one. Take apart a real-world study claiming a 34 per cent mortality reduction. Each has a briefing, working space and a debrief with the full arithmetic.

• Five AI role plays. Spoken practice against a counterpart who pushes back the way the real one does: a US benefit manager, a German assessor, a national payer refusing on budget impact, your own commercial director, and a hospital committee with a fixed budget in July.

• Live workbooks. A US gross-to-net and Medicare negotiation calculator, an early access route comparator, and two EU HTA planning tools. Every formula works, so you change an assumption and watch the answer move.

• A decoder of 130 terms, in Word and PDF, with three columns: the acronym, what it stands for, and what it actually means.

Current as of 2026. Positions verified against primary sources: the first joint clinical assessment report adopted in April 2026, the first negotiated Medicare prices in force since January 2026, the UK payment rate for 2026, and the reformed early access schemes in France, Germany, Italy, the United Kingdom and the United States.

How to use it. Chapter 1 gives you the whole field in twelve minutes and three routes through the course: an interview in two weeks, learning it properly, or one specific topic. You do not have to take sixteen chapters in order, and you should not.

Chapters 2 and 3 are written guides with downloadable tools rather than video. Video runs from chapter 4 onwards.

Embark on an enlightening adventure into the pivotal world of Pharmaceutical Market Access, a crucial domain pivotal to the advancement of healthcare and patient well-being. This detailed and expansive course delves deep into the core aspects of Health Technology Assessment (HTA), Real World Evidence (RWE), Health Economics and Outcomes Research (HEOR), Patient Access, Innovation, and Early Access, uncovering the layers and complexities involved in bringing revolutionary medical treatments from conception to the hands of those in need.

With a curriculum designed for both seasoned professionals and newcomers eager to leave their mark in the pharmaceutical sector, this course offers a rare glimpse into the strategic and operational facets of market access. You will be equipped with the knowledge to not only understand but also influence the multifaceted decision-making processes that determine the success and reach of new healthcare solutions.

Through a blend of theoretical knowledge and practical insights, gain the expertise to navigate the regulatory landscapes, understand the economic impact, and advocate for patient access to essential medications. Learn from industry experts and case studies that bring to life the challenges and triumphs of ensuring that groundbreaking therapies are available, affordable, and attainable for patients around the globe.

This course is your gateway to becoming a key player in the pharmaceutical industry, where you'll be empowered to drive innovation, influence healthcare policy, and contribute to the shaping of future medical breakthroughs. By enrolling, you're not just signing up for a course; you're stepping into a community dedicated to making a lasting impact on global health. Your journey towards mastering Pharmaceutical Market Access starts here. Seize this opportunity to be at the forefront of healthcare evolution, and play a part in delivering hope and healing to millions worldwide.